Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9234686 | 0.83 | MAPT (0.46) | MAPTL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL28807259 | 0.81 | MAPT (0.49) | MAPTL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL9933428 | 0.80 | ADRB1 (0.52) | MAPTHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL1536526 | 0.79 | CTSB (0.47) | MAPTL3MBTL1MEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29277728 | 0.77 | MAPT (0.41) | MAPTL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL3833537 | 0.75 | LMNA (0.48) | MAPTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL9424119 | 0.74 | LMNA (0.62) | MAPTL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL28025203 | 0.73 | ATR (0.35) | ALDH1A1KDM4E | |
| SCHEMBL20025114 | 0.73 | SLC6A2 (0.38) | IRAK4ALDH1A1 | |
| SCHEMBL31133207 | 0.71 | CYP2A13 (0.53) | MEN1KMT2AHSD17B10ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | claimed |
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4056569-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-09-14 | — | — | EP | disclosed |
| EP-3672962-B1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| CN-105143209-A | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG | 2015-12-09 | — | — | CN | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | MAPT 60/4885L3MBTL1 2793/4885MEN1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.